GLP1R and familial pancreatic carcinoma: By analyzing the reported adverse events in the US Food and Drug Administration’s database, Elashoff reported that treatment with DPP4 inhibitor sitagliptin or GLP-1R agonist exenatide increased the risk of pancreatitis and pancreatic cancer as compared with other therapies.